Featured Stocks Overview: Actinium Pharmaceuticals, Inc. (NYSE:ATNM), FIRST REPUBLIC BANK (NYSE:FRC)

Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

B. Riley FBR Maintains Actinium Pharmaceuticals, Inc. (NYSE:ATNM)’s stock to Buy with the price target of $3. This rating was issued on 7/12/18. The stock recently closed its previous session at $0.64 by showing a percentage change of -7.78% from its previous day closing price of $0.69.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Actinium Pharmaceuticals, Inc. (NYSE:ATNM) in which B. Riley FBR Initiates Coverage On Actinium Pharmaceuticals, Inc. (NYSE:ATNM) to Buy by settling a price target of $2.8 on 12/06/17. Roth Capital Initiates Coverage on the stock to Buy on 8/25/16 by stationing a price target of $5. H.C. Wainwright Initiates Coverage on the company’s stock to Buy on 2/29/16 by setting a price target of $8. FBR Capital Initiates Coverage on Actinium Pharmaceuticals, Inc. (NYSE:ATNM) to Outperform with a price target of $12.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) currently has a consensus Price Target of $4.29. While some analysts have a High Price target for the stock of $6 and a Low Price Target of $3.

Several sell side analysts reviewed their recommendations on Actinium Pharmaceuticals, Inc. (NYSE:ATNM) where 1 analyst have rated the stock as Strong Buy, 4 analysts said it’s a Buy, 0 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 1. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) reported its Actual EPS of $-0.04/share. The analysts offering Earnings Estimates for the company were believing that Actinium Pharmaceuticals, Inc. (NYSE:ATNM) could bring EPS of $-0.07/share. The difference between Actual EPS and Estimated EPS was 0.03 Percent. Thus the company showed an Earnings Surprise of 42.9 Percent.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has a market capitalization of 71.21 Million. The stock traded with the volume of 1.16 Million shares in the last trading session. The stock touched its high share price of $0.87 on 09/26/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 04/24/18 as $0.33. The company has a 1 Year high price target of $3.95. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -14.99%. The Moving Average SMA50 is -9.54% while SMA200 is 12.44%.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is currently showing its ROA (Return on Assets) of -99.9%. The Return on Investment (ROI) is at 0% while it’s Return on Equity (ROE) value stands at -127.9%. The stock currently shows its YTD (Year to Date) performance of -3.6 percent while its Weekly performance value is -10.43%. The Monthly and Yearly performances are -15.28 percent and -2.17 percent respectively. The Relative Volume value measured for Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is 1.09. The Average Volume (3 months) is 1.06 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. ATNM has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 3.56 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York.

FIRST REPUBLIC BANK (NYSE:FRC)

Raymond James Maintains FIRST REPUBLIC BANK (NYSE:FRC)’s stock to Outperform with the price target of $104. This rating was issued on 10/15/18. The stock recently closed its previous session at $86.62 by showing a percentage change of -0.74% from its previous day closing price of $87.27.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on FIRST REPUBLIC BANK (NYSE:FRC) in which BMO Capital Maintains FIRST REPUBLIC BANK (NYSE:FRC) to Market Perform by settling a price target of $102 on 7/16/18. Wells Fargo Maintains the stock to Market Perform on 6/26/18 by stationing a price target of $100. Citigroup Initiates Coverage On the company’s stock to Buy on 6/18/18 by setting a price target of $120. UBS Initiates Coverage On FIRST REPUBLIC BANK (NYSE:FRC) to Neutral with a price target of $100.

FIRST REPUBLIC BANK (NYSE:FRC) currently has a consensus Price Target of $102.35. While some analysts have a High Price target for the stock of $115 and a Low Price Target of $92.

Several sell side analysts reviewed their recommendations on FIRST REPUBLIC BANK (NYSE:FRC) where 4 analyst have rated the stock as Strong Buy, 4 analysts said it’s a Buy, 14 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 2.13. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, FIRST REPUBLIC BANK (NYSE:FRC) reported its Actual EPS of $1.19/share. The analysts offering Earnings Estimates for the company were believing that FIRST REPUBLIC BANK (NYSE:FRC) could bring EPS of $1.2/share. The difference between Actual EPS and Estimated EPS was -0.01 Percent. Thus the company showed an Earnings Surprise of -0.8 Percent.

FIRST REPUBLIC BANK (NYSE:FRC) has a market capitalization of 14.27 Billion. The stock traded with the volume of 1.16 Million shares in the last trading session. The stock touched its high share price of $106.75 on 08/21/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 10/24/18 as $84.47. The company has a 1 Year high price target of $102.76. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -5.66%. The Moving Average SMA50 is -11.42% while SMA200 is -10.11%.

FIRST REPUBLIC BANK (NYSE:FRC) is currently showing its ROA (Return on Assets) of 0.8%. The Return on Investment (ROI) is at 23.3% while it’s Return on Equity (ROE) value stands at 10.6%. The stock currently shows its YTD (Year to Date) performance of -0.02 percent while its Weekly performance value is -3.63%. The Monthly and Yearly performances are -9.74 percent and -13.01 percent respectively. The Relative Volume value measured for FIRST REPUBLIC BANK (NYSE:FRC) is 1.03. The Average Volume (3 months) is 1.12 Million.

The stock currently has its Annual Dividend of $0.72 and an annual Dividend Yield of 0.83 Percent. FRC has P/E (Price to Earnings ttm) value of 17.84, Forward P/E of 16.07, P/C (Price to cash per share) of 2.8 and Price to Free Cash Flow (P/FCF) value of 18.58. The stock is showing its Operating Margin of 75.9 percent.

Company Profile:

First Republic Bank operates as a commercial bank offering private banking, business banking, real estate lending and wealth management services in California. The bank’s services are catered to accounting firms, architecture and design, business management firms, entertainment/media, family offices, hedge funds, independent schools, investment firms, law firms, medical firms, non-profit organizations, private equity funds/firms, property management firms, venture capital firms and etc. Services offered by First Republic include asset allocation, trust administration, custody, asset management, brokerage, private placements, ATM rebate checking, money market checking, passbook savings, and certificates of deposit and etc. The Company’s product include family mortgages, co-op and condominium loans, home equity lines of credit, bridge loans, and construction-to-permanent loans; commercial lending and personal lending. First Republic Bank is headquartered in San Francisco, California.